EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Document 62013CN0691
Case C-691/13: Request for a preliminary ruling from the Conseil d’État (France) lodged on 22 October 2013 — Les Laboratoires Servier SA v Ministre des affaires sociales et de la santé, Ministre de l'Économie et des Finances
Case C-691/13: Request for a preliminary ruling from the Conseil d’État (France) lodged on 22 October 2013 — Les Laboratoires Servier SA v Ministre des affaires sociales et de la santé, Ministre de l'Économie et des Finances
Case C-691/13: Request for a preliminary ruling from the Conseil d’État (France) lodged on 22 October 2013 — Les Laboratoires Servier SA v Ministre des affaires sociales et de la santé, Ministre de l'Économie et des Finances
OJ C 85, 22.3.2014, p. 16–16
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
22.3.2014 |
EN |
Official Journal of the European Union |
C 85/16 |
Request for a preliminary ruling from the Conseil d’État (France) lodged on 22 October 2013 — Les Laboratoires Servier SA v Ministre des affaires sociales et de la santé, Ministre de l'Économie et des Finances
(Case C-691/13)
2014/C 85/28
Language of the case: French
Referring court
Conseil d’État
Parties to the main proceedings
Applicant: Les Laboratoires Servier SA
Defendants: Ministre des affaires sociales et de la santé, Ministre de l’Économie et des Finances
Question referred
Does Article 6(2) of Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems (1) require that reasons be stated for decisions as to inclusion or re-inclusion in the list of medicinal products eligible for reimbursement by the health insurance funds which — by limiting, in comparison with the application made, the therapeutic indications giving rise to eligibility for reimbursement, or by making that reimbursement subject to conditions relating to, inter alia, the qualifications of the prescribing doctors, the organisation of care or the follow-up of patients, or in any other way — make the reimbursement by the health insurance funds available to only some of the patients liable to benefit from the medicinal product or only in certain circumstances?